Figure 1

A


Survival rate
% survival
120
100
80
60
40
20
0
6 19 26 33 40 47 55
Days post-tumor challenge
Naive B6/Bom
pCDNA+ GMCSF
Angiomotin
Angiomotin + GMCSF

B


Survival rate
% survival
120
100
80
60
40
20
0
7 14 18 21 24 28 32 35
Days post-tumor challenge
Naive B6/Bom
pCDNA + GMCSF
Angiomotin
Angiomotin + GMCSF

Figure 2

A


Survival rate
Survival (% of 5 balb/c mice)
100
80
60
40
20
0
0 13 27 39 46
Days post-challenge
PCDNA + GM
Angiomotin + GM

B


Mean tumor volume (of 5 balb c mice)
tumor volume mm3
5000
4000
3000
2000
1000
0
7 13 20 27 35 39 43 46
Days post challenge
PCDNA+ GM
Angiomotin +GM

Figure 3


Surival post-challenge
% survival (of 10 mice)
100
80
60
40
20
0
0 5 12 19 23 27 29 34
Days post-challenge
PCDNA
PCDNA+ GM
Angiomotin
Angiomotin + GM


Mean Tumor Volume
4000
3500
3000
2500
2000
1500
1000
500
0
0 5 12 15 19 23 27 29
Days after challenge
PCDNA
PCDNA+ GM
Angiomotin
Angiomotin + GM

Figure 4

SEQUENCE 1 **(SEQ.ID.NO.1)**

MPRAQPSSASYQPVPADPFAIVSRAQQMVEILSDENRNLRQELE

GCYEKVARLQKVETEIQRVSEAYENLVKSSSKREALEKAMRNKLEGEIRRMHDFNRDL

RERLETANKQLAEKEYEGSEDTRKTISQLFAKNKESQREKEKLEAELATARSTNEDQR

RHIEIRDQALSNAQAKVVKLEEELKKKQVYVDKVEKMQQALVQLQAACEKREQLEHRL

RTRLERELESLRIQQRQGNCQPTNVSEYNAAALMELLREKEERILALEADMTKWEQKY

LEENVMRHFALDAAATVAAQRDTTVISHSPNTSYDTALEARIQKEEEEILMANKRCLD

MEGRIKTLHAQIIEKDAMIKVLQQRSRKEPSKTEQLSCMRPAKSLMSISNAGSGLLSH

SSTLTGSPIMEEKRDDKSWKGSLGILLGGDYRAEYVPSTPSPVPPSTPLLSAHSKTGS

RDCSTQTERGTESNKTAAVAPISVPAPVAAAATAAAITATAATITTTMVAAAPVAVAA

AAAPAAAAAPSPATAAATAAAVSPAAAGQIPAAASVASAAAVAPSAAAAAAVQVAPAA

PAPVPAPALVPVPAPAAAQASAPAQTQAPTSAPAVAPTPAPTPTPAVAQAEVPASPAT

GPGPHRLSIPSLTCNPDKTDGPVFHSNTLERKTPIQILGQEPDAEMVEYLI

Figure 4

SEQUENCE 2 (SEQ.ID.NO.2)

```
1    ccaggagctg ccttggcagt cacgcccctt ccttccgagg agctttctgg ctgcctaaac
61   tggtagaccc cctgaattac tcctccatct ccgctctctt tcgcctcctc ttctcttagt
121  tctctccgcc tccccctcaa ctaccaccac ctccagtcag tctcgcctcc ggctatccgc
181  tgctccaccc tctggcccgg tatcctgcct gtccgctgcc accaaggaga gcccggacgg
241  agcagcgagg aggggagcag ccgggagttg gggcttcccc cctgcccatc cctggccgct
301  ggcccgggac cgaagccact tgagcgagca gagagtcgtc accttgtctt ctttgccttc
361  agggagctgc taagaaggac aaataagata gcagagtgaa agagcttttg tctccttaga
421  aggaaggctg agaaactaaa ggccagcgca ggacatctca ttgccattgt cagccaggaa
481  ctcgcagcct cacagcccta cttcttctct gacctctggg gggtccttgc ccttgctaca
541  atctccacca tccactagat tgtctcctgc ccgacacccc ttggtcccaa accagggaga
601  ccattcagct cacctgccta ggccgcagca gcatttcctt cctaatcagg ctcaccaggg
661  ggatcattac cgtctctccc aacctggcct gagtcagcag cagcagcaac agcagcagca
721  gcaccatcat caccatcacc accaacaaca gcagcagcag cagccacagc agcagccagg
781  agaagcctat tcagctatgc ctcgggctca gccatcctct gcttcttatc agccagtgcc
841  agcagaccct tttgccattg tttccagagc ccagcagatg gttgagatcc tctcagacga
901  gaaccggaac ttgaggcaag agttggaagg atgctatgag aaggtggcaa gactgcagaa
961  ggtggagaca gaaatccagc gcgtctcgga ggcatatgag aacctcgtga agtcatcctc
1021 caaaagagag gccctagaga aagccatgag aaacaagcta gagggcgaga ttcggaggat
1081 gcatgatttc aacagggatc tgagagagcg tctagagact gccaacaagc agcttgcaga
1141 gaaggaatat gaggggtcag aggacaccag aaaaaccatc tcgcagctct ttgcaaaaaa
1201 taaagaaagc cagcgtgaga aggagaagct ggaagcggag ctggccactg cccgttctac
1261 caatgaggac caaagacgac acatcgaaat ccgagatcag gccctgagta atgcccaggc
1321 caaggtggta aagctggaag aagagctgaa aaagaagcaa gtgtacgttg acaaggtgga
1381 gaagatgcag caggcccttg tacagctcca ggcagcatgt gaaaaacgtg agcagctaga
1441 gcaccgtctc cggacacgac tggagaggga actggaatcc ctgagaatcc agcagcgtca
1501 gggcaactgt cagcccacca acgtttcaga atacaatgct gccgcactga tggagctcct
1561 tcgggagaaa gaggagagga ttctggctct ggaagctgat atgacaaagt gggagcagaa
1621 atatttggag gagaatgtga tgagacattt tgctctggat gctgctgcaa ctgtggctgc
1681 tcagagggac acaacagtca tcagtcactc tcctaacacc agctatgaca cagctctaga
1741 agctcgcatc cagaaagagg aggaagaaat cttgatggcc aataagcgtt gccttgacat
1801 ggagggcagg attaagaccc tccatgccca gattattgag aaggatgcca tgatcaaagt
1861 actccagcag cgttcccgga aggagccgag caagacagag cagctgtcgt gcatgcggcc
1921 agcgaagtct ctgatgtcca tttccaatgc tggatcaggc ttgctctccc actcatccac
1981 cctgactggc tcccccatca tggaagaaaa gcgagacgac aagagctgga aggggagcct
2041 aggcattctc ctgggtggag actaccgtgc tgaatatgtc ccttccacac cctcgcctgt
2101 gccaccctcg actcccctgc tctcggctca ctccaagaca ggcagccgag actgcagtac
2161 ccaaactgaa cgtgggacgg aatcgaacaa aactgcagct gttgctccca tctctgttcc
```

Figure 4

2221 tgctccagtt gctgctgccg ccactgctgc cgccatcact gccactgctg ccaccatcac
2281 caccaccatg gtagctgctg ctccagttgc tgttgctgct gctgctgctc cagctgctgc
2341 tgctgccccg tctccagcca ctgccgctgc tactgctgct gctgtttctc cagctgctgc
2401 tggtcagatt ccagctgctg cctctgttgc ctcagctgct gccgttgctc cttctgctgc
2461 tgctgctgct gctgttcagg ttgctccagc tgctccggct ccagttccag ctccggctct
2521 ggttccggtt ccagctccag cagcggctca ggcttctgct cctgctcaga ctcaggcacc
2581 aacttcagct ccggctgtgg ctccaactcc agctccaact ccaactccag ctgtggctca
2641 ggctgaggtt cctgcaagtc cagctaccgg tcctggacca catcgtttgt ctataccaag
2701 tttgacctgc aatccagaca aaacagatgg gcctgtgttc cactccaata ctctggaaag
2761 aaaaactccc attcagatcc tgggacaaga gcctgatgca gagatggtgg aatatctcat
2821 ctaaacggcc aaatcaagag ctgcagatta tcagcaaaaa tgcttttaat catttcccc
2881 cttttattgg ttcttgtttt gagggtgagg acaagggttg tggggagggg atgtttttta
2941 acaggacttt ttattggaac aatgtactac ttgagtaata ccatgtgaac accagtctat
3001 tttggtatgc ttagggagta cctctaaaga cagattaatc agaatgtgct ctaaagctta
3061 ttgtttgaat ttatacgaat actgggactg ttaacaggtg gctatacatc gacgttttca
3121 atgtgcttaa atttgtttaa attttccata ttctagatca ttttttattg aagagcacag
3181 tatgtgtgga agacagtgta taacacgtag tttggaagtg ggaagctaga gagaattgag
3241 tgtgtgctgt tttgtatagt tactatcctg tgcagcagct ggagaaagca ctcacctcag
3301 gcttacaaaa gggaatagtt tcaggagcta tgtaagctgg aaaaaaggta gggagttttg
3361 gggtgcagaa gggtactgga gctaattttt tcttccagtt tcccagctac cctgccccag
3421 ggaattgtgt ttgtcttcat ttcagtggtg ctttggaaat ggattctttt ggttccctcc
3481 tggaggttca tacattcata tatatgctct ggagtaattt atgcatttgg ataattaata
3541 tattgctttc agatgctggg agagtacatt aactgagtga tgcgcaactt cctctctctt
3601 agggaattag accatcagag gccttgatgg agagttgcat ggggtgctat atgcagactt
3661 ccatggtttg tgtgtagcca tgaacacagc ttgcttgcat ttagtaagac caatcagctt
3721 agtgtttatt tcttctacag cacagattca ctggctgggt ctccagtctc aaattgccaa
3781 tcatttgcaa agtgaggaag gatctttgtt gacaggttga atgctttgaa tttctggtga
3841 ctactttgaa ataacttgtt ttgtttgtca aattctaagc atatgtctta aaaggcattt
3901 ttgactatca cctccaaggg aatagcttga gaaacccaaa gtactatgct gcagtcgggg
3961 gagaggtgga ttgcagcagt atcctcaact acctcttctc actgtcagtg acaccatctt
4021 ggaatacctt tgggaagcag caggaaatgt gcatgtgggt agagatcaaa ggaggcaatg
4081 gctccaagcc ttgccatagg gctgcctcca aggacacaga aggatgccag ttgccacagg
4141 tccctgccct gtgtcacctg tctgcccttc attaaggtga gaaatctgca gatagcatca
4201 ttaagatcag ttttaagggg tatagggagg gtgagggaag tgggggtgt taggtaaggg
4261 ttgggggtag aggttttggg atgtcttagt tagaaaccag attaatagaa gagtaggcct
4321 gatatattac atcatgagcc atagtggtgg gaaagaactt tagcaatata gccctacctc
4381 ctcattttag tgatgaggaa tctgagaact ggagaggttc agtgactttt tgaaagtcat
4441 acaacacagc taaccattat gccaatcacc atgcttattt tgggaaactc tttatctttt
4501 ttaaattcca ttttatgaaa aggcatcttc atggtccagg gaatatgtat cttgtaaaat

Figure 4

4561 gtacctggtt ggagtagctt gtccagtctt gacaaactac tgaatttctg tcttgcctct
4621 ccttcagtgc cttttaaaag gttttccctt ttctgatctg catttcaaca tagagtcaca
4681 taaatgtccc cctgagaaac caatcccact tctttctagg agattgggta tcttagataa
4741 tcttttgggg ttcctctgtg agtataggaa tggtatcctt cctaattatc ttccaaagga
4801 attattttgt gtgtgtgcct gtgtgtgtgt agagacataa aggagggtga tgtgattttc
4861 agctagtcct ttcacatttt caataatgag gtaatcatgt tacatacaca ttagtcctca
4921 gttataaagt gaatctcaga tagaaattaa aagtgcagtt gtgttaagac tctttcatac
4981 taccctttag tcataaggag aaaaaaacac tcaaatagta gaagcagcaa gtagcaaact
5041 tcaggagagc tactttctat ccaaataatt taaaaaacac ttttcaccta ctcctttcat
5101 ggttataaca cattggcaga ctttttgctg gctctgggag ccatgatttt aatcacattc
5161 tgcaaggtga caaatgtcat acattccaca ttgtgtggta gccatctctt tagactcatg
5221 tgttttgggg aaaggaagaa gttcttggct gagtactatt ttgaactttc cagaaccctc
5281 tcacaccaga gacagttctt ctctgttcag tttccaatcc ccgataattt gctaaaataa
5341 cattgtacat ccaagagagg gaagaagagt atgtcagtat attatgcaga agatagatac
5401 agccttttca gaagatctcc actagttttt gttccaaaaa ttcaagttta tgggagaaat
5461 ctcaattagc cacctttttca cagttgtgtg gatataacat ttgggggatc tttctggact
5521 cctacctatc tgtgcatttt accggcacct caggaaagga gggtgaccag gttgtcttag
5581 cttgtactgc ttggtgatct ctgaggacct tctaattcag ttgtacccca gtgttccatg
5641 tatagaaaaa cttcattaga acaaacttta cttgatatga aactcctatt aacagtcttt
5701 ttttgaaata aaaagtagct tgagctttct tttaaaatca tgtatcttga ttgttgattt
5761 aatgaaggat ttccttttaa tgctgctttt gagcttcaag gtaataggac agcaggaacc
5821 taaaatatct gccatcatct gccataggaa agatacccag agacccatca tgttctcttt
5881 ttgttgttac actgttgggt gggtataaca attggaaaat gaacaaactg attgattgtg
5941 caaactactt tttatgacaa gcctaaaccc tcataatgcg gcagcttaaa gtgtatacat
6001 atgcactaac tttgatcaat tatattctca tatctgttag ctacacagtc tcctattatc
6061 tcaattgctt atgtgcatat ggaatatgtt acttaaaacg tgtgcattct tactgaaaat
6121 gttttcaaag gaaggtatca gctgtgggct aattgccacc aatttcagcc tgccacgatt
6181 cttggaaata tgtcttccaa gtgccatcca tcatcagtag gacaagtgtc gggagtttgt
6241 ttatttttt ccagtagcaa cgatgggtta catggagcca tgaaacctcc ttctggcctc
6301 ccttgtgatt aatggcatgt gtttgtaaaa tggatagctg gggttggcag atggctagag
6361 aagaatcgcc tttggtttaa aatgtatgtg gtcccctaat gattgtgacc ccattctgta
6421 atcaactgag ctagttccaa taaagttaag caggtttaaa tccactttgt gcctatcttt
6481 tcactgacaa taaagttagc tattttaaaa tgcagtaccg tgtggaaaat gctttggtgt
6541 ttacccgaca gaggctttat ttgtgctgta tcagtgatta ctttcaattc agtatgcagt
6601 gaaattgcct ttcaagggca gcgtgcagca gaatttgcat ttgcttgaag tatggaatgt
6661 gattatagat tataaagtat taagacaaca ccacaggccg catgctctaa tcggtctctt
6721 tatatactca ggcagcatat attaaaagct ttgcatcttt ttatcttctg gtttctaggg
6781 ataaaatgat ggccacccaa agcagagaat ttatcctttg gttagcattt tggaaggccc
6841 cttgatattc cttttgtacc cttgttctga tgccaattca tcagtttt

Figure 5


Anti-angiogenic vaccination:
ANGIOMOTIN ALONE
tumor free mice (%)
100
80
60
40
20
0
untreated
pcDNA3
angiomotin
p<0.0001
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
weeks of age

Figure 6


Two component therapy:
Amot
p<0.0001
pcDNA3
untreated
TMEC
TMEC + angiomotin
tumor free mice (%)
100
80
60
40
20
0
0
10
20
30
40
50
60
weeks of age

Figure 7


Tumor transplantation model
tumor mean diameter (mm)
0
2
4
6
8
10
prevention
untreated
-21:-7
5
4+1
0
10
20
30
40
50
days after challenge

Figure 8

A


ANGIO #6 BALB/c mice after the fourth Angiomotin electroporation
lum signal
3000000
2500000
2000000
1500000
1000000
500000
0
1
2
3
4
5
6
dilution factor 500 to 16000
mean Angio#6 No3
mean Angio#6 No10
mean Angio#6 No80
mean Angio#6 No5
mean Angio#6 No11
mean control

B


ANGIO #1A BALB-neuT mice electroporated twice with Angiomotin, serum from week 21
lum signal
1000000
900000
800000
700000
600000
500000
400000
300000
200000
100000
0
1
2
3
4
5
6
dilution factor 500 to 16000
mean Angio#1A No4
mean Angio#1A No10
mean Angio#1A No20
mean Angio#1A No5
mean Angio#1A No18
mean control

Figure 8

C


ANGIO #2 BALB-neuT mice electroporated twice with Angiomotin and TMEC, serum from week 21
lum signal
1000000
900000
800000
700000
600000
500000
400000
300000
200000
100000
0
1
2
3
4
5
6
dilution factor 500 to 16000
mean Angio#2 No0
mean Angio#2 No5
mean Angio#2 No40
mean Angio#2 No4
mean Angio#2 No6
mean control

Figure 9



Y-axis: vascular density as analyzed by PECAM immunohistochemical staining

Serie 1: Control vaccinated mice
Serie 2: TMEC vaccinated mice
Serie 3: Angiomotin vaccinated mice
Serie 4: Angiomotin + TMEC vaccinated mice